Job opportunity at UKHSA - we are looking for 2 epidemiologists to join the respiratory virus section in the Immunisations division. Link to apply below & happy to chat. www.civilservicejobs.service.gov.uk/csr/index.cg...

Our study on the effectiveness of the COVID-19 vaccines in preventing disease in pregnant women and their infants is now published in BMJ Medicine. https://bmjmedicine.bmj.com/content/3/1/e000696

FluSurvey is one of @UKHSA's systems for monitoring respiratory infections. It is a critical tool which helps us better understand infection and illness in the community. Sign up to take part! https://flusurvey.net/en (for UK residents only)

First real-world data on the vaccine effectiveness (VE) of the Sanofi booster now out. TLDR; the Sanofi booster provides good protection (30-50% on top of the protection remaining from a waned autumn booster) against hospitalisation in those aged 75+. https://www.medrxiv.org/content/10.1101/20...

In our latest pre-print we estimate vaccine effectiveness (VE) against hospitalisation and disease severity for BQ.1, CH.1.1. and XBB.1.5. TLDR; vaccines provide good protection against all sub-lineages & there were no major differences in severity. http://www.medrxiv.org/content/10.1101/20...

Exciting opportunity - looking for a motivated senior epidemiologist for a permanent position in my team. Salary: £40,867-£45,998 Closes: 20 Aug 2023 Please R/T. Happy to chat with anyone looking to apply. https://www.jobs.nhs.uk/candidate/jobadvert/K9919-23-0265 @pubhealthjobsuk @IDDjobs @P...

Great news for RSV prevention in England! The JCVI published their statement today recommending that an RSV immunisation programme, that is cost effective, should be developed for both infants and older adults. https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-...

Great to present our latest work today at #ECCMID2023

Very excited to be in Copenhagen for #ECCMID23! I’ll be speaking in Hall M tomorrow (Sunday 16th April), presenting our latest vaccine effectiveness estimates of bivalent boosters and against current variants of concern; BQ.1, CH.1.1 and XBB.1.5. Come say hi! ☺️

Now out as a pre-print - our latest data on the long term duration of protection of the monovalent COVID-19 vaccines, and vaccine effectiveness (VE) of the bivalent booster vaccines against hospitalisation in England. https://www.medrxiv.org/content/10.1101/2023.03.31.23288018v1

Our paper on the effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England has been featured in the Editors' Highlights of @NatureComms 👇 https://www.nature.com/collections/jcbdhegiab

Our paper on the effectiveness of the AstraZeneca (AZ; ChAdOx1-S) vaccine when used as a booster is now peer-reviewed and out https://www.nature.com/articles/s41467-022-35168-7.pdf

Vaccine effectiveness (VE) of the bivalent booster vaccines against COVID-19 hospitalisation in England -> first data now out in the UKHSA vaccine surveillance report 1/7 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1121345/vaccine-surveilla...

Our latest pre-print where we estimate vaccine effectiveness (VE) against hospitalisation following infection with the Omicron sub-lineages BA.4 and BA.5 in England is now up: https://www.medrxiv.org/content/10.1101/2022.08.31.22279444v1

Now peer-reviewed and published @TheLancetInfDis, our study on vaccine effectiveness (VE) against symptomatic disease and hospitalisation for BA.2 compared to BA.1. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00309-7/fulltext

The first real-world data on the vaccine effectiveness (VE) of the AstraZeneca booster against symptomatic disease and hospitalisation with Delta and Omicron - new pre-print from us this week. https://khub.net/documents/135939561/338928724/Effectiveness+of+ChAdOx1-S+COVID-19+booster+vaccination+...

Pre-print of our study investigating vaccine effectiveness (VE) against symptomatic disease caused by the Omicron sub-lineage BA.2 is out on medRxiv today https://www.medrxiv.org/content/10.1101/2022.03.22.22272691v1

Our most comprehensive analysis so far on the protection conferred by vaccines against hospitalisation over time is published today in the UKHSA Vaccine Surveillance report https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1063023/Vaccine-surveillanc...

Our peer-reviewed paper estimating vaccine effectiveness against symptomatic disease with Omicron is now out! https://www.nejm.org/doi/full/10.1056/NEJMoa2119451?query=featured_home

Great to see a little paper from my PhD has been selected for the @SciReports Editor's Choice Negative Results Collection. https://www.nature.com/collections/gcifjebabg?sap-outbound-id=E5B79DC85EA936125CD326DA799BB1857D82D192&utm_source=hybris-campaign&utm_medium=email&utm_campaign=111_BADM01_00...

Two important updates from our team this week: - Vaccine effectiveness (VE) against symptomatic disease after Omicron BA.2 shows that VE remains unchanged - VE against death after Omicron BA.1 shows VE is 95% at 2+ weeks after booster 1/7 Full report https://assets.publishing.service.gov.uk/g...

This week's updated analysis from our team on vaccine effectiveness against Omicron infection is now published in the UKHSA Technical Briefing. Good news - protection from the boosters against severe disease continues to be well maintained. https://assets.publishing.service.gov.uk/government/up...

This week, we were able to estimate vaccine effectiveness (VE) against hospitalisation for the first time. In short, good news. VE after a booster is close to 90%. The full update from our team is published in this week's technical briefing update: https://assets.publishing.service.gov.uk/govern...

An update from our team on the latest vaccine effectiveness (VE) estimates against symptomatic infection with the Omicron variant has now been published in the UKHSA Variant Technical Briefing 33 (page 24). https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_dat...

Our first initial estimates of vaccine effectiveness (VE) against symptomatic disease with the Omicron variant are now out. In short, VE remains high following a Pfizer booster after AZ or Pfizer, but is reduced after two doses. More below 👇 1/11

Great to be able to share our review on the role of neutrophils during respiratory viral infections, with @cjohansson_lab. Now out 👉https://doi.org/10.1038/s41385-021-00397-4

Second paper of my PhD is out! 🥳 A small but important study (we think🙂) on some things we noticed, with surprise, that neutrophils *don't* do during RSV infection. With great thanks to everyone involved, especially Christina, Marina & @cjohansson_lab https://www.nature.com/articles/s41598-0...

Really enjoyed presenting my data on the signalling pathways regulating neutrophil recruitment and activation in RSV infection last week at the UK-Russia Young Medics Association conference @SechenovUni. Thanks for inviting me!